Allison and colleagues. Contrary to the explosive success of dual immune checkpoint blockade for treating cancers, a major hurdle still yet persist is that immune-related adverse events (irAEs) ...

1Northwestern University, Chicago, Illinois.

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, ...

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Individually, colistin decreases the effect of anti-CTLA-4 therapy in MCA205 tumors, while ampicillin, metronidazole, and vancomycin decrease responses to anti-PD-L1 therapy in MC38 tumors.

Interestingly, CTLA-4 knockout mice and mice that lack expression of CTLA-4 just in T REG develop fatal, early-onset lymphoproliferative disease. 1,4 In addition, expression and signaling of CTLA ...